Peer-reviewedCC BYJournal of clinical medicine29 Sep 2026

Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy

Qi Chen¹
Wenbing Duan¹
Jinsong Jia¹
Jing Wang¹
Xiaosu Zhao¹
Guorui Ruan¹
Hongxia Shi¹
Yingjun Chang¹
Xiaojun Huang¹
Hao Jiang¹

¹Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, National Clinical Research Center for Hematologic Disease, Peking University Institute of Hematology, Peking University People’s Hospital, , Beijing 100044, China

Effects of azacitidine combined with venetoclax on inflammatory markers and overall response rate in elderly patients with newly diagnosed acute myeloid leukemia
Hui-Fang Liu, Cheng Lian, Xian-Guang Zhu
BMC Geriatrics1 Jul 2026Peer-reviewedCC BYFull textGeneral medicineDOAJ
Multimodal Artificial Intelligence Fusion Models to Predict Response to Venetoclax and Azacitidine in Patients with Newly Diagnosed Acute Myeloid Leukemia
J.-N. Eckardt, I. Srivastava, K. Gill +12
medRxiv12 Oct 2026PreprintCC BY-NC-NDFull textGeneral medicinemedRxiv
Response to Venetoclax and Azacitidine in Induction-Refractory Adult Acute Myeloid Leukemia with UBTF Tandem Duplication and Associated Aberrant Splicing: A Case Report
Seigi Oshima, Kazuhisa Chonabayashi, Takashi Sakamoto +11
Internal Medicine15 Oct 2026Peer-reviewedCC BY-NC-NDFull textGeneral medicineJ-STAGE
Stabilization of the PP2A-B56α complex overcomes venetoclax-azacitidine resistance by impairing OXPHOS in AML
Silvia Romero-Murillo, Irene Peris, Anna Maria Lucianò +13
JCI Insight15 Sep 2026Peer-reviewedCC BY 4.0Full textGeneral medicinePMC
Patient-tailored azacitidine, venetoclax and gilteritinib triplet therapy appear to improve tolerability while preserving encouraging clinical outcomes in FLT3-mutated relapsed/refractory AML.
Matilda Arvidsson Kvissberg, Christer Nilsson, Niklas Landberg +6
Annals of hematology23 Oct 2026Peer-reviewedCC BYFull textGeneral medicineEurope PMCDOAJ

Cite

BibTeX

@article{chen2026efficacy,
  title = {{Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy}},
  author = {Qi Chen and Wenbing Duan and Jinsong Jia and Jing Wang and Xiaosu Zhao and Guorui Ruan and Hongxia Shi and Yingjun Chang and Xiaojun Huang and Hao Jiang},
  journal = {Journal of clinical medicine},
  year = {2026},
  month = sep,
  url = {https://europepmc.org/article/PMC/PMC13665879},
  note = {CC BY},
}

RIS

TY  - JOUR
TI  - Efficacy of Sorafenib Combined with Venetoclax and Azacitidine in Newly Diagnosed FLT3-ITD-Mutant Acute Myeloid Leukemia: Remission Efficacy and Prognostic Influence of Post-Remission Consolidation Therapy
AU  - Qi Chen
AU  - Wenbing Duan
AU  - Jinsong Jia
AU  - Jing Wang
AU  - Xiaosu Zhao
AU  - Guorui Ruan
AU  - Hongxia Shi
AU  - Yingjun Chang
AU  - Xiaojun Huang
AU  - Hao Jiang
PY  - 2026
DA  - 2026/09/29
JO  - Journal of clinical medicine
UR  - https://europepmc.org/article/PMC/PMC13665879
SN  - 2077-0383
ER  -

Related

Cite